The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease

Antioxidants & Redox Signaling
L KupershmidtO Weinreb

Abstract

The aim of the present study was to evaluate the therapeutic effect of the novel neuroprotective multi-target nontoxic, lipophilic, brain permeable monoamine oxidase inhibitor and iron chelating-radical scavenging drug, M30, on the neuropathology and deficits of spatial learning and memory in amyloid precursor protein (APP) and presenilin 1 (PS1) double-transgenic (Tg) Alzheimer's disease (AD) mice. Here, we report that systemic treatment of APP/PS1 Tg mice with M30 for 9 months, significantly attenuated cognitive impairments in a variety of tasks of spatial learning and memory retention, working memory, learning abilities, anxiety levels, and memory for novel food and nesting behavior. Furthermore, we found that M30 reduced cerebral iron accumulation accompanied by a marked decrease in several AD-like phenotypes, including cerebral APP levels, amyloid β (Aβ) levels and plaques, phospho-APP and phospho-tau. Signaling studies revealed that M30 markedly downregulated the levels of phosphorylated cyclin-dependent kinase 5 and increased protein kinase B and glycogen synthase kinase 3β phosphorylation. Accumulation and deposition of brain iron is central to various neuropathological processes in AD, including oxidative stress, amylo...Continue Reading

References

May 1, 1984·Journal of Neuroscience Methods·R Morris
Jul 17, 1998·Journal of the Neurological Sciences·M A LovellW R Markesbery
Sep 30, 2000·Brain Research. Brain Research Reviews·G J Siegel, N B Chauhan
Feb 13, 2001·Biochemical and Biophysical Research Communications·I MizutaS Kuno
Mar 29, 2001·Physiological Reviews·D J Selkoe
Oct 5, 2001·Bulletin of Experimental Biology and Medicine·S E Shemyakov
Apr 12, 2003·Trends in Neurosciences·Ashley I Bush
Oct 15, 2003·The Journal of Cell Biology·Ming-Sum LeeLi-Huei Tsai
Sep 1, 1951·Canadian Journal of Psychology·M S RABINOVITCH, H E ROSVOLD
Apr 24, 2004·Annals of the New York Academy of Sciences·Kostas Pantopoulos
Jun 3, 2004·Annals of Neurology·Fabrizio TrincheseOttavio Arancio
Oct 12, 2004·Journal of Neurocytology·Donna L MoolmanMichael L Shelanski
May 18, 2005·Neurochemical Research·Maria F FalangolaJoseph A Helpern
Jan 13, 2006·The Pharmacogenomics Journal·F FumagalliM A Riva
May 12, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Tobias EngelJosé J Lucas
Jun 9, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Natalia TraissardJean-Christophe Cassel
Jan 20, 2007·Genes, Brain, and Behavior·R S ReisererM P McDonald
Aug 11, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Wen ZhuWeidong Le
Aug 19, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Undurti N Das
Feb 12, 2008·Behavioural Brain Research·R M J DeaconJ N P Rawlins
Nov 7, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Yun DingGuo-Huang Fan
Apr 14, 2009·Journal of Alzheimer's Disease : JAD·Muralidhar L HegdePaolo Zatta

❮ Previous
Next ❯

Citations

Jul 31, 2013·Neuropharmacology·R AnandAbbas Ali Mahdi
Jan 28, 2014·Pharmaceuticals·Hailin ZhengMoussa Youdim
Jan 6, 2016·Chemical Communications : Chem Comm·Meital Eckshtain-LeviLaurent Benisvy
Oct 30, 2013·Neuropathology and Applied Neurobiology·M HadzhievaC Mawrin
Mar 17, 2015·Chembiochem : a European Journal of Chemical Biology·Jeffrey S Derrick, Mi Hee Lim
Aug 22, 2015·Neurodegenerative Disease Management·Jeffrey R Liddell
Jul 15, 2015·Life Sciences·Melita Salkovic-PetrisicMoussa B H Youdim
Mar 23, 2015·Neurobiology of Disease·Peng LeiAshley I Bush
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Luisa S PimentelA Claudio Cuello
Feb 5, 2013·Free Radical Biology & Medicine·Orly WeinrebTamar Amit
Dec 17, 2014·Behavioural Brain Research·Chaoyun LiZhiyuan Zhang
Mar 20, 2012·Mechanisms of Ageing and Development·Lana KupershmidtOrly Weinreb
Aug 8, 2014·Chemical Society Reviews·Kevin J Barnham, Ashley I Bush
Jun 3, 2016·Frontiers in Neuroscience·Mercedes UnzetaJosé Marco-Contelles
Sep 7, 2016·Frontiers in Neuroscience·Rona R RamsayMassimo Valoti
Jul 18, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Rona R Ramsay, Keith F Tipton
Mar 4, 2015·Perspectives in Medicinal Chemistry·Hailin ZhengMoussa Youdim
Nov 1, 2018·Journal of Neurochemistry·Xiao Tian HuangHai Yan Zhang
Jan 12, 2019·British Journal of Pharmacology·Sara NiksereshtScott Ayton
Mar 9, 2018·Journal of Neural Transmission·Rona R Ramsay, Alen Albreht
Aug 10, 2017·Reviews in the Neurosciences·Sotirios Apostolakis, Anna-Maria Kypraiou
Aug 4, 2020·Journal of Alzheimer's Disease : JAD·Shalini S RaoPaul A Adlard
Oct 28, 2019·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Karla AcevedoAshley I Bush
Oct 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew Gleason, Ashley I Bush
Feb 23, 2021·Journal of Alzheimer's Disease : JAD·Yang-Yang WangZhi-You Cai
Jul 30, 2021·Free Radical Biology & Medicine·Bin Lin, Moussa B H Youdim

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

Sharp 2000
Sharp
Bio
Laser

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.